CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that, under its collaboration agreement with Merck & Co., Inc., a preclinical milestone was achieved with one of its novel Toll-Like Receptor (TLR) 9 agonists used as an adjuvant in cancer vaccines. As a result, Idera is eligible to receive a milestone payment from Merck.
